HLA-C and cancer: First, it explains how neoepitopes with a high or low affinity to MHC may be effective against cancers (because the pMHC affinity is less relevant than a low pMHC-TCR avidity, although a lower pMHC I affinity does bias the TCR repertoire toward the more desirable lower pMHC-TCR avidity).